JP2010516237A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010516237A5 JP2010516237A5 JP2009545947A JP2009545947A JP2010516237A5 JP 2010516237 A5 JP2010516237 A5 JP 2010516237A5 JP 2009545947 A JP2009545947 A JP 2009545947A JP 2009545947 A JP2009545947 A JP 2009545947A JP 2010516237 A5 JP2010516237 A5 JP 2010516237A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleotide sequence
- protein
- group
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims 4
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 4
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 4
- 102100034388 Netrin-4 Human genes 0.000 claims 4
- 101710121532 Netrin-4 Proteins 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 230000003796 beauty Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 2
- 102000009840 Angiopoietins Human genes 0.000 claims 2
- 108010009906 Angiopoietins Proteins 0.000 claims 2
- 102100033553 Delta-like protein 4 Human genes 0.000 claims 2
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 2
- 102000004207 Neuropilin-1 Human genes 0.000 claims 2
- 108090000772 Neuropilin-1 Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 229940076783 lucentis Drugs 0.000 claims 2
- 229940092110 macugen Drugs 0.000 claims 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 229940080607 nexavar Drugs 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 229960003407 pegaptanib Drugs 0.000 claims 2
- 210000003668 pericyte Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229960003876 ranibizumab Drugs 0.000 claims 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 2
- 229960003787 sorafenib Drugs 0.000 claims 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 2
- 229960001796 sunitinib Drugs 0.000 claims 2
- 229940034785 sutent Drugs 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 238000011278 co-treatment Methods 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 208000001491 myopia Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07290075A EP1947114A1 (en) | 2007-01-19 | 2007-01-19 | Mutated netrin 4, fragments thereof and uses thereof as drugs |
| PCT/EP2008/050662 WO2008087224A2 (en) | 2007-01-19 | 2008-01-21 | Mutated netrin 4, fragments thereof and uses thereof as drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010516237A JP2010516237A (ja) | 2010-05-20 |
| JP2010516237A5 true JP2010516237A5 (OSRAM) | 2011-03-10 |
Family
ID=38123893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009545947A Pending JP2010516237A (ja) | 2007-01-19 | 2008-01-21 | 変異ネトリン４、そのフラグメント及び薬剤としてのその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8420780B2 (OSRAM) |
| EP (2) | EP1947114A1 (OSRAM) |
| JP (1) | JP2010516237A (OSRAM) |
| CA (1) | CA2675754A1 (OSRAM) |
| WO (1) | WO2008087224A2 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1355666B1 (en) | 2000-12-22 | 2012-06-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (RGM) and its modulators |
| JP5089397B2 (ja) * | 2004-11-22 | 2012-12-05 | サントル ナシオナル ドゥ ラ ルシェルシェ シアンティフィク | 変異ネトリン４、その断片及びこれらの薬剤としての使用 |
| WO2007039256A2 (de) | 2005-09-30 | 2007-04-12 | Abbott Gmbh & Co. Kg | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| WO2010007144A2 (en) * | 2008-07-18 | 2010-01-21 | Centre National De La Recherche Scientifique | New mutated netrin 4 proteins, fragments thereof and their uses as drugs |
| WO2010142040A1 (en) * | 2009-06-09 | 2010-12-16 | The Royal Institution For The Advancement Of Learning/Mcgill University | Novel netrin derivatives and uses thereof |
| CA2780069C (en) | 2009-12-08 | 2018-07-17 | Abbott Gmbh & Co. Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
| MX391536B (es) | 2012-01-27 | 2025-03-21 | Abbvie Deutschland | Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7402660B2 (en) * | 2000-08-02 | 2008-07-22 | The Johns Hopkins University | Endothelial cell expression patterns |
| JP5089397B2 (ja) * | 2004-11-22 | 2012-12-05 | サントル ナシオナル ドゥ ラ ルシェルシェ シアンティフィク | 変異ネトリン４、その断片及びこれらの薬剤としての使用 |
-
2007
- 2007-01-19 EP EP07290075A patent/EP1947114A1/en not_active Withdrawn
-
2008
- 2008-01-21 EP EP08735406A patent/EP2102233A2/en not_active Withdrawn
- 2008-01-21 JP JP2009545947A patent/JP2010516237A/ja active Pending
- 2008-01-21 US US12/523,074 patent/US8420780B2/en not_active Expired - Fee Related
- 2008-01-21 WO PCT/EP2008/050662 patent/WO2008087224A2/en not_active Ceased
- 2008-01-21 CA CA002675754A patent/CA2675754A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010516237A5 (OSRAM) | ||
| JP7536737B2 (ja) | Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン | |
| US11517623B2 (en) | Anti-PD-1 antibodies, antigen-binding portions thereof and checkpoint regulator antogonists comprising the same | |
| US10647773B2 (en) | Trispecific antagonists | |
| Bates et al. | Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein | |
| TW200902552A (en) | Recombinant anti-epidermal growth pactor receptor antibody compositions | |
| DK2921503T3 (en) | Human antibody to human epidermal growth factor receptor and coding gene and its use | |
| CN109790215A (zh) | 异源二聚体免疫球蛋白构建体和其制备方法 | |
| HRP20211453T1 (hr) | Liječenje amd uporabom aav sflt-1 | |
| JP2011521662A5 (OSRAM) | ||
| JP2013532971A (ja) | ホモ二量体タンパク質コンストラクト | |
| CN114380906B (zh) | 一种抗il-17a的单域抗体及其用途 | |
| JP2016519063A5 (OSRAM) | ||
| Benhnia et al. | Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5 | |
| JP2022540571A (ja) | 変異したＴＧＦβ１－ＲＩＩ細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト | |
| JP2024084773A (ja) | Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体 | |
| TW201106971A (en) | Antigen-binding proteins | |
| CN110563841A (zh) | 一种人源化抗Grb2单克隆抗体、及其制备方法和应用 | |
| WO2022132929A2 (en) | Multispecific antibody molecules and uses thereof | |
| WO2022141378A1 (zh) | 一种抗pd-1的单域抗体 | |
| Chen et al. | Selection of affinity-improved neutralizing human scFv against HBV PreS1 from CDR3 VH/VL mutant library | |
| JP2022536850A (ja) | Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ | |
| JP2022537324A (ja) | Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１抗体の組合せ | |
| CN119039430B (zh) | 靶向结核分枝杆菌MctB的保护性单克隆抗体及制备方法和应用 | |
| CN105198992A (zh) | 一种人源抗创伤弧菌溶血素蛋白(vvh)抗体的制备方法与应用 |